Online inquiry

IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4322MR)

This product GTTS-WQ4322MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets C1S gene. The antibody can be applied in Cold agglutinin disease (CAD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001346850.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 716
UniProt ID P09871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ4322MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3619MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ2731MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG-139
GTTS-WQ10029MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA L19-131 I
GTTS-WQ15166MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA T1h
GTTS-WQ4540MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ8523MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Hu3F8
GTTS-WQ15256MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ3115MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA APN311
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW